参考文献/References:
[1] Sun H,Saeedi P,Karuranga S,et al.IDF diabetes atlas:global,regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J].Diabetes Res Clin Pract,2022,183:109119.DOI:10.1016/j.diabres.2021.109119.
[2] Weng J,Zhou Z,Guo L,et al.Incidence of type 1 diabetes in China,2010-13:population based study[J].BMJ,2018,360:j5295.DOI:10.1136/bmj.j5295.
[3] 中华医学会糖尿病学分会.中国1型糖尿病诊治指南(节选)[J].糖尿病临床,2013,7(3):108-114.DOI:10.3969/j.issn.1672-7851.2013.03.002.
[4] Insel RA,Dunne JL,Atkinson MA,et al.Staging presymptomatic type 1 diabetes:a scientifific statement of JDRF,the endocrine society,and the American diabetes association[J].Diabetes Care,2015,38(10):1964-1974.DOI:10.2337/dc15-1419.
[5] PociotF,Lernmark Å.Genetic risk factors for type 1 diabetes[J].Lancet,2016,387(10035):2331-2339.DOI:10.1016/S0140-6736(16)30582-7.
[6] Krischer JP,Lynch KF,Schatz DA,et al.The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children:the TEDDY study[J].Diabetologia,2015,58(5):980-987.DOI:10.1007/s00125-015-3514-y.
[7] Steck AK,Vehik K,Bonifacio E,et al.Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes:the environmental determinants of diabetes in the young(TEDDY)[J].Diabetes Care,2015,38(5):808-813.DOI:10.2337/dc14-2426.
[8] Endesfelder D,Zu Castell W,Bonifacio E,et al.Time-resolved autoantibody profiling facilitates stratification of preclinical type 1 diabetes in children[J].Diabetes,2019,68(1):119-130.DOI:10.2337/db18-0594.
[9] Krischer JP,Type 1 Diabetes TrialNet Study Group.The use of intermediate endpoints in the design of type 1 diabetes prevention trials[J].Diabetologia,2013,56(9):1919-1924.DOI:10.1007/s00125-013-2960-7.
[10] Dayan CM,Korah M,Tatovic D,et al.Changing the landscape for type 1 diabetes:the first step to prevention[J].Lancet,2019,394(10205):1286-1296.DOI:10.1016/S0140-6736(19)32127-0.
[11] Gale EA,Bingley PJ,Emmett CL,et al.European nicotinamide diabetes intervention trial(ENDIT):a randomised controlled trial of intervention before the onset of type 1 diabetes[J].Lancet,2004,363(9413):925-931.DOI:10.1016/S0140-6736(04)15786-3.
[12] Martinez MM,Spiliopoulos L,Salami F,et al.Heterogeneity of beta-cell function in subjects with multiple islet autoantibodies in the TEDDY family prevention study-TEFA[J].Clin Diabetes Endocrinol,2022,7(1):23.DOI:10.1186/s40842-021-00135-6.
[13] Skyler JS,Krischer JP,Wolfsdorf J,et al.Effects of oral insulin in relatives of patients with type 1 diabetes:the diabetes prevention trial--type 1[J].Diabetes Care,2005,28(5):1068-1076.DOI:10.2337/diacare.28.5.1068.
[14] Vehik K,Cuthbertson D,Ruhlig H,et al.Long-term outcome of individuals treated with oral insulin:diabetes prevention trial-type 1(DPT-1)oral insulin trial[J].Diabetes Care,2011,34(7):1585-1590.DOI:10.2337/dc11-0523.
[15] Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group; Krischer JP,Schatz DA,Bundy B,et al.Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes:a randomized clinical trial[J].JAMA,2017,318(19):1891-1902.DOI:10.1001/jama.2017.17070.
[16] Sosenko JM,Skyler JS,Herold KC,et al.Slowed metabolic decline after 1 year of oral insulin treatment among individuals at high risk for type 1 diabetes in the diabetes prevention trial-type 1(DPT-1)and TrialNet oral insulin prevention trials[J].Diabetes,2020,69(8):1827-1832.DOI:10.2337/db20-0166.
[17] Näntö-Salonen K,Kupila A,Simell S,et al.Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease:a double-blind,randomised controlled trial[J].Lancet,2008,372(9651):1746-1755.DOI:10.1016/S0140-6736(08)61309-4.
[18] Elding Larsson H,Lundgren M,Jonsdottir B,et al.Safety and efficacy of autoantigenspecific therapy with 2 doses of alumformulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes:a randomized clinical trial[J].Pediatr Diabetes,2018,19(3):410419.DOI:10.1111/pedi.12611.
[19] Douthwaite J,Moisan J,Privezentzev C,et al.A CD80-Biased CTLA4-Ig fusion protein with superior in vivo efficacy by simultaneous engineering of affinity,selectivity,stability,and FcRn binding[J].J Immunol,2017,198(1):528-537.DOI:10.4049/jimmunol.1600682.
[20] Herold KC,Gitelman SE,Ehlers MR,et al.Teplizumab(anti-CD3 mAb)treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial[J].Diabetes,2013,62(11):3766-3774.DOI:10.2337/db13-0345.
[21] Herold KC,Bundy BN,Long SA,et al.An anti-CD3 antibody,Teplizumab,in relatives at risk for type 1 diabetes[J].N Engl J Med,2019,381(7):603-613.DOI:10.1056/NEJMoa1902226.
[22] Sims EK,Bundy BN,Stier K,et al.Teplizumab improves and stabilizes beta cell function in antibody positive high-risk individuals[J].Sci Transl Med,2021,13(583):eabc8980.DOI:10.1126/scitranslmed.abc8980.
[23] Clark M,Kroger CJ,Tisch RM.Type 1 Diabetes:a chronic Anti-Self-inflammatory response[J].Front Immunol,2017,8:1898.DOI:10.3389/fimmu.2017.01898.
相似文献/References:
[1]袁扬,孙子林.PANDER与β细胞凋亡[J].国际内分泌代谢杂志,2007,(04):253.
[2]刘媛 刘超.1型糖尿病青少年儿童心理行为问题研究进展[J].国际内分泌代谢杂志,2015,(01):63.[doi:10.3760/cma.j.issn.1673-4157.2015.01.016]
Liu Yuan,Liu Chao..Psychological problems in adolescents and children with type 1 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(03):63.[doi:10.3760/cma.j.issn.1673-4157.2015.01.016]
[3]王思倩,吴锦丹.肠促胰素对1型糖尿病患者血糖及胰岛功能的影响[J].国际内分泌代谢杂志,2015,(03):196.[doi:10.3760/cma.j.issn.1673-4157.2015.03.015]
Wang Siqian,Wu Jindan..Effects of incretin on blood glucose and islet function in type 1 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(03):196.[doi:10.3760/cma.j.issn.1673-4157.2015.03.015]
[4]李亚兰,项洁,卜瑞芳.1型糖尿病的DiaPep277免疫治疗[J].国际内分泌代谢杂志,2014,(03):169.[doi:10.3760/cma.j.issn.1673-4157.2014.03.007]
Li Yalan,Xiang Jie,Bu Ruifang..Immunotherapy with DiaPep277 peptide in type 1 diabetes[J].International Journal of Endocrinology and Metabolism,2014,(03):169.[doi:10.3760/cma.j.issn.1673-4157.2014.03.007]
[5]陈晔,李艳玲,王坚.天然免疫细胞在1型糖尿病中的作用[J].国际内分泌代谢杂志,2014,(03):184.[doi:10.3760/cma.j.issn.1673-4157.2014.03.011]
Chen Ye,Li Yanling,Wang Jian..Role of innate immune cells in type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2014,(03):184.[doi:10.3760/cma.j.issn.1673-4157.2014.03.011]
[6]蔡芸莹 苏恒.1型糖尿病的非胰岛素治疗[J].国际内分泌代谢杂志,2015,(06):388.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.007]
Cai Yunying,Su Heng.Noninsulin management in type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(03):388.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.007]
[7]李明珍,聂秀玲,孙丽荣.高尿酸血症与糖代谢异常的关系[J].国际内分泌代谢杂志,2016,36(04):217.[doi:10.3760/cma.j.issn.1673-4157.2016.04.01]
Li Mingzhen,Nie Xiuling,Sun Lirong.Relationship between hyperuricemia and abnormalities of glucose metabolism[J].International Journal of Endocrinology and Metabolism,2016,36(03):217.[doi:10.3760/cma.j.issn.1673-4157.2016.04.01]
[8]冉慧,苏青.碳水化合物反应元件结合蛋白与胰岛β细胞增殖
及分化的关系[J].国际内分泌代谢杂志,2017,37(03):189.[doi:10.3760/cma.j.issn.1673-4157.2017.03.012]
Ran Hui,Su Qing..Relationship between carbohydrate response element binding protein and proliferation, differentiation of islet β cell[J].International Journal of Endocrinology and Metabolism,2017,37(03):189.[doi:10.3760/cma.j.issn.1673-4157.2017.03.012]
[9]王静 张梅.胰高血糖素在1型糖尿病治疗中的研究进展[J].国际内分泌代谢杂志,2018,38(01):19.[doi:10.3760/cma.j.issn.1673-4157.2018.01.005]
Wang Jing,Zhang Mei.Research progress of glucagon for the treatment of type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2018,38(03):19.[doi:10.3760/cma.j.issn.1673-4157.2018.01.005]
[10]朱婧 蒋晓红 项守奎 许晨 华飞.1型糖尿病患者尿酸水平与血脂异常的
相关性研究[J].国际内分泌代谢杂志,2020,40(01):16.[doi:10.3760/cma.j.issn.1673-4157.2020.01.004]
Zhu Jing,Jiang Xiaohong,Xiang Shoukui,et al.Correlation between uric acid level and dyslipidemia in patients with type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2020,40(03):16.[doi:10.3760/cma.j.issn.1673-4157.2020.01.004]